Medicines Discovery Catapult (MDC) has announced a £1 million investment in two U.K. biotech companies, Flip Therapeutics and Nascent Therapeutics, both focused on innovative treatments for chronic diseases such as psoriasis and neurodegenerative disorders. This funding, sourced from Innovate UK, aims to propel the development of high-potential therapies that address significant unmet medical needs.
Alongside the financial backing, MDC will offer its translational drug discovery expertise and extensive network of advisors to support these companies. Flip Therapeutics is pioneering a method to reprogram T cells in vivo, potentially transforming immune responses in patients suffering from autoimmune conditions. This approach could lead to a new class of immune-modulating therapies, significantly impacting patient care and healthcare costs.
Meanwhile, Nascent Therapeutics is leveraging mitochondrial biology to create disease-modifying therapies for neurodegenerative diseases, initially targeting Parkinson’s. Their innovative platform aims to enhance mitochondrial transfer, addressing the decline in cellular resilience associated with aging. The support from MDC is expected to accelerate their research and development, ultimately aiming to deliver novel treatments that could reshape therapeutic strategies in chronic disease management.
Start your 7-day trial and see what the database can do →
